TYRX, Inc. raises $20 million in private financing
Proceeds will Support Continued Commercialization of the AIGISRx® Antibacterial Envelope and Development of Next Generation Products
Monmouth Junction, NJ (December 8, 2010) – TYRX, Inc., the leader in the commercialization of implantable medical devices designed to help reduce surgical-site infections associated with implantable pacemakers and defibrillators, announced today that it has raised $20 million in venture capital funding. The funding was led by new investor, HLM Venture Partners along with previous investors Clarus Ventures and Pappas Ventures. The financing round also included $4 million in debt financing from Comerica Bank. In connection with the financing, Edward L. Cahill, Managing Partner, HLM Venture Partners, will join TYRX’s Board of Directors.
© 2021 Pappas Capital, LLC. ALL RIGHTS RESERVED.